HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality

201933 citationsJournal Articlegold Open Access

Authors

David M. Richards · Apogenix (Germany)

Viola Marschall · Biotest (Germany)

Katharina Billian-Frey · Apogenix (Germany)

Karl Heinonen · Apogenix (Germany)

Christian J. Merz · Apogenix (Germany)

Mauricio Redondo Müller · Apogenix (Germany)

Julian P. Sefrin ·

Abstract

In this manuscript, we describe the development of HERA-GITRL, a true GITR agonist with a clearly defined mechanism of action. By clustering six receptor chains in a spatially well-defined manner, HERA-GITRL induces potent agonistic activity without being dependent on additional FcγR-mediated crosslinking.

Topics & Keywords

Immune Cell Function and Interaction T-cell and B-cell Immunology CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 7, Issue 1, pp. 191-191

DOI: 10.1186/s40425-019-0671-4

Field-Weighted Citation Impact: 1.31